Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous polyclonal tumor infiltrating lymphocytes LYL845

A preparation of autologous, epigenetically reprogrammed, polyclonal tumor infiltrating lymphocytes (TILs), with potential immunomodulating and antineoplastic activities. The autologous TILs LYL845 are prepared and expanded ex vivo by co-culturing autologous tumor cells with specific Epi-R cell culture media containing optimized cytokine composition and cell activation which creates TILs enriched with CD8-positive T cells with diverse tumor-reactive clones and an enhanced proportion of stem-like T cells. Upon administration, the autologous TILs LYL845 may target and kill tumor cells and secrete pro-inflammatory cytokines. LYL845 shows increased durability of expanded TILs, enhanced polyclonality and increased tumor-reactive cytolytic T cells compared to TILs derived from the standard process.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous TILs LYL845
Code name:LYL 845
LYL-845
LYL845
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search